Header Logo

Connection

JOSEPH JANKOVIC to Tetrabenazine

Back to Details
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Tetrabenazine.
JOSEPH JANKOVIC
Connection Strength
6.622
Tetrabenazine
  1. Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial. JAMA Netw Open. 2021 10 01; 4(10):e2128204.
    View in: PubMed
    Score: 0.713
  2. Real-World Experience With VMAT2 Inhibitors. Clin Neuropharmacol. 2019 Mar/Apr; 42(2):37-41.
    View in: PubMed
    Score: 0.596
  3. Deutetrabenazine for the treatment of Huntington's chorea. Expert Rev Neurother. 2018 08; 18(8):625-631.
    View in: PubMed
    Score: 0.571
  4. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013 Feb; 28(2):210-5.
    View in: PubMed
    Score: 0.388
  5. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011 Nov; 11(11):1509-23.
    View in: PubMed
    Score: 0.358
  6. Advances in the pharmacological management of Huntington's disease. Drugs. 2010 Mar 26; 70(5):561-71.
    View in: PubMed
    Score: 0.321
  7. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol. 2008 May-Jun; 31(3):127-33.
    View in: PubMed
    Score: 0.281
  8. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007 Jan 15; 22(2):193-7.
    View in: PubMed
    Score: 0.257
  9. Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord. 2007 Jan; 22(1):10-3.
    View in: PubMed
    Score: 0.256
  10. Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol. 2006 Sep-Oct; 29(5):259-64.
    View in: PubMed
    Score: 0.251
  11. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother. 2006 Jan; 6(1):7-17.
    View in: PubMed
    Score: 0.239
  12. Real-World Experiences with VMAT2 Inhibitors in Pediatric Hyperkinetic Movement Disorders. Tremor Other Hyperkinet Mov (N Y). 2025; 15:26.
    View in: PubMed
    Score: 0.230
  13. Real-world experience with VMAT2 inhibitors in Tourette syndrome. J Neurol. 2023 Sep; 270(9):4518-4522.
    View in: PubMed
    Score: 0.200
  14. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol. 2002 Nov-Dec; 25(6):300-2.
    View in: PubMed
    Score: 0.192
  15. Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial. JAMA Netw Open. 2021 10 01; 4(10):e2129397.
    View in: PubMed
    Score: 0.178
  16. Treatment of Tardive Dyskinesia. Neurol Clin. 2020 05; 38(2):379-396.
    View in: PubMed
    Score: 0.160
  17. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999 Aug; 156(8):1279-81.
    View in: PubMed
    Score: 0.153
  18. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. Drugs. 2018 04; 78(5):525-541.
    View in: PubMed
    Score: 0.140
  19. Treatment options for chorea. Expert Rev Neurother. 2018 Jan; 18(1):51-63.
    View in: PubMed
    Score: 0.136
  20. Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea. JAMA Neurol. 2017 08 01; 74(8):977-982.
    View in: PubMed
    Score: 0.133
  21. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997 Feb; 48(2):358-62.
    View in: PubMed
    Score: 0.129
  22. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016 Dec; 17(18):2461-2470.
    View in: PubMed
    Score: 0.127
  23. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. JAMA. 2016 Jul 05; 316(1):40-50.
    View in: PubMed
    Score: 0.124
  24. Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia. Drugs. 2016 May; 76(7):779-87.
    View in: PubMed
    Score: 0.122
  25. Dramatic response of facial stereotype/tic to tetrabenazine in the first reported cases of neuroferritinopathy in the United States. Mov Disord. 2010 Oct 30; 25(14):2470-2.
    View in: PubMed
    Score: 0.084
  26. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology. 1988 Mar; 38(3):391-4.
    View in: PubMed
    Score: 0.069
  27. Coexistent tardive dyskinesia and parkinsonism. Clin Neuropharmacol. 1987 Dec; 10(6):511-21.
    View in: PubMed
    Score: 0.068
  28. Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. Parkinsonism Relat Disord. 2020 08; 77:141-145.
    View in: PubMed
    Score: 0.041
  29. Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology. 1993 May; 43(5):937-41.
    View in: PubMed
    Score: 0.025
  30. Tardive tremor. Mov Disord. 1992; 7(1):53-7.
    View in: PubMed
    Score: 0.023
  31. Tardive oculogyric crises. Neurology. 1989 Nov; 39(11):1434-7.
    View in: PubMed
    Score: 0.020
  32. Lesch-Nyhan syndrome: a study of motor behavior and cerebrospinal fluid neurotransmitters. Ann Neurol. 1988 May; 23(5):466-9.
    View in: PubMed
    Score: 0.018
  33. Tardive dystonia in patients with Tourette's syndrome. Mov Disord. 1988; 3(3):274-80.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.